Review
Biochemistry & Molecular Biology
Rose Parisi, Hemali Shah, Neil H. Shear, Michael Ziv, Alina Markova, Roni P. Dodiuk-Gad
Summary: The rapid development of anti-cancer therapy has improved treatment outcomes for cancer patients, but it has also been associated with the occurrence of bullous dermatologic adverse events (DAE), which can negatively impact patients' quality of life and treatment continuation. Effective management of these adverse events is crucial for minimizing treatment interruptions and maintaining the anti-tumor effect.
Article
Chemistry, Medicinal
Lukas Kraehenbuehl, Stephanie Schneider, Laura Pawlik, Joanna Mangana, Phil Cheng, Reinhard Dummer, Barbara Meier-Schiesser
Summary: Recent progress in the treatment of advanced melanoma has led to improved survival, but also increased skin toxicity. This study investigated biopsy-proven cutaneous adverse events in melanoma treatment over 10 years. Skin adverse events were more common with targeted therapies compared to immune checkpoint blockade. A wide range of skin adverse events were observed, with different types associated with specific treatment classes.
Article
Dermatology
Sean Singer, Sally Y. Tan, Anna K. Dewan, Matthew Davids, Ann S. LaCasce, Steven P. Treon, Nicole R. LeBoeuf
Summary: This study retrospectively investigated 19 patients who developed cutaneous eruptions while taking ibrutinib, and found that the cutaneous toxicities of ibrutinib overlap with those associated with EGFR inhibitors, but most patients were still able to continue ibrutinib therapy except for petechiae.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Review
Oncology
Lucy Y. Liu, Joyce M. C. Teng, Sheri L. Spunt, Jenna L. Strelo, Bernice Y. Kwong, Lisa C. Zaba
Summary: Cutaneous adverse events (cAEs) caused by targeted anticancer treatments and immune checkpoint inhibitors are common in pediatric cancer patients. It is essential to diagnose and manage these events promptly to optimize cancer-directed therapy and enhance quality of life. This systematic review summarizes dermatologic toxicities associated with targeted anticancer treatments and immune checkpoint inhibitors.
PEDIATRIC BLOOD & CANCER
(2021)
Review
Immunology
Yuhong Wang, Chen Chen, Wei Du, Yixin Zhou, Lina He, Shaodong Hong, Li Zhang
Summary: This study evaluated the reporting quality of adverse events (AE), especially immune-related AE (irAE), in immunotherapy clinical trials. A total of 123 publications were included and assessed using a 16-point harm reporting quality score (HRQS). The findings showed that AE reporting in immunotherapy trials is suboptimal, highlighting the need for improvement and standardization of reporting practices.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Leah L. Thompson, Jordan T. Said, Edward B. Li, Jaewon Yoon, Nira A. Krasnow, Gabriel E. Molina, Nicole J. Polyakov, Ruth K. Foreman, Nicole R. LeBoeuf, Steven T. Chen
Summary: Evaluation of dermatologists' diagnostic accuracy for cutaneous immune-related adverse events from immune checkpoint inhibitors showed that experienced supportive oncodermatologists may benefit patient care through increased diagnostic accuracy, emphasizing the importance of integrating skin biopsy and oncodermatology referral in supportive cancer care.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Hui-Te Hsu, Chu-Chun Yu, Yun-Hsiang Lee, Jui-Chun Chan, Chia-Yu Chu
Summary: The severity of pruritus, photosensitivity, and alopecia is associated with the health-related quality of life (HRQoL) of patients receiving EGFR-TKI therapy. The use of patient-reported outcome measurements helps clinicians capture the actual impact of symptoms on physical, social-emotional, and functional well-being.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Ruofei Du, Xin Wang, Lixia Ma, Leon M. Larcher, Han Tang, Huiyue Zhou, Changying Chen, Tao Wang
Summary: This study found that 61.0% of patients undergoing targeted therapy experienced ADRs, including skin damage, fatigue, mucosal damage, hypertension, and gastrointestinal discomfort. Older age, lower education level, multiple comorbidities, longer medication time, drug combination, and intravenous administration were associated with a higher risk of ADRs.
Article
Oncology
Pietro Sollena, Nikolaou Vasiliki, Elias J. Kotteas, Alexander J. Stratigos, Davide Fattore, Armando Orlandi, Maria Mannino, Marcello Di Pumpo, Monika Fida, Michela Starace, Zoe Apalla, Maria Concetta Romano, Julia Riganti, Sonia Segura, Azael Freites Martinez, Gabriella Fabbrocini, Vincent Sibaud, Ketty Peris
Summary: Treatment with CDK4/6 inhibitor in combination with endocrine therapies can improve progression-free survival in patients with hormone receptor-positive, HER2-negative, advanced breast cancer. However, limited data exists on its cutaneous adverse events. This retrospective study investigated the prevalence, types, and management of cutaneous adverse events during CDK4/6 inhibitor treatment.
Article
Oncology
Lucy Rose, Patrick M. M. Schnell, Lindsey Radcliff, Maryam Lustberg, Brittany Dulmage
Summary: For patients with cancer, alopecia caused by chemotherapy has negative effects on personal identity, body image, self-esteem, quality of life, and medical decision-making. Scalp cooling is a technique that can prevent this side effect by causing localized vasoconstriction of blood vessels. A study investigated factors influencing patients' decisions to use scalp cooling, and found that patient age, race, insurance status, and chemotherapy regimen played important roles.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Multidisciplinary Sciences
Satoshi Nishioka, Masaki Asano, Shuntaro Yada, Eiji Aramaki, Hiroshi Yajima, Yuki Yanagisawa, Kyoko Sayama, Hayato Kizaki, Satoko Hori
Summary: This study aimed to build deep-learning models for extracting signals of adverse events (AE) limiting activities of daily living (ADL) from patients' narratives. The T5 model showed the best performance in identifying articles describing AE limiting ADL or all AE.
SCIENTIFIC REPORTS
(2023)
Article
Dermatology
Mario E. Lacouture, Jennifer Choi, Alice Ho, Jonathan Leventhal, Beth N. McLellan, Anneke Andriessen, Maxwell B. Sauder, Edith Mitchell
Summary: The US Cutaneous Oncodermatology Management (USCOM) project aims to improve cancer patients' and survivors' quality of life by offering tools for preventing and managing cutaneous adverse events (cAEs) through education and skincare interventions before, during, and after cancer treatment.
JOURNAL OF DRUGS IN DERMATOLOGY
(2021)
Review
Dermatology
Anthony M. Rossi, Brian P. Hibler, Cristian Navarrete-Dechent, Mario E. Lacouture
Summary: While the long-term survival of cancer patients has greatly increased in recent decades, the treatments that lead to cure or remission can have secondary effects on the skin, hair, and nails. These dermatologic changes can have negative impacts on quality of life and function, proving to be visually disfiguring reminders of past illness. Efforts to improve these sequelae and restore the appearance and function of skin and appendages are crucial for normalization and improved quality of life in cancer survivors.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Oncology
Prahathishree Mohanavelu, Mira Mutnick, Nidhi Mehra, Brandon White, Sparsh Kudrimoti, Kaci Hernandez Kluesner, Xinyu Chen, Tim Nguyen, Elaina Horlander, Helena Thenot, Vamsi Kota, Cassie S. Mitchell
Summary: Frontline therapy for BCR-ABL (Ph+) chronic myeloid leukemia (CML) involves tyrosine kinase inhibitors (TKIs) treatment. A systematic meta-analysis comparing the incidence of gastrointestinal adverse events (GI AEs) in a large heterogeneous CML population as a function of TKI type showed significant differences in GI AE profiles between different TKIs but minimal differences in patient survival. Optimal TKI selection for chronic phase CML patients without resistant mutations should consider the TKI AE profile, comorbidities, and lifestyle.
Review
Medicine, General & Internal
Alyce M. Kuo, Alina Markova
Summary: Immune checkpoint blockade (ICB) shows promising results in cancer treatment, but it can also cause severe dermatologic adverse events (DAEs), which may limit its use. Proper identification and treatment of these DAEs are crucial to maximize the effectiveness of ICB therapy.
FRONTIERS IN MEDICINE
(2022)
Review
Oncology
Lauren Milton, Tara Behroozian, Natalie Coburn, Maureen Trudeau, Yasmeen Razvi, Erin McKenzie, Irene Karam, Henry Lam, Edward Chow
Summary: The Edmonton Symptom Assessment Scale (ESAS) is a validated tool used to measure patient symptoms in cancer patients. Studies reviewed show that ESAS can be used to predict patient survival time, emergency department visits, symptoms associated with decreased quality of life, and generate health utility scores.
SUPPORTIVE CARE IN CANCER
(2021)
Review
Oncology
Tara Behroozian, Lauren T. Milton, Neil H. Shear, Erin McKenzie, Yasmeen Razvi, Irene Karam, Kucy Pon, Henry Lam, Emily Lam, Edward Chow
Summary: This review assessed the quality and efficacy of tools used in scoring radiation dermatitis in breast cancer patients and found that tools assessing clinician-reported outcomes had moderate correlation with biophysical parameter measurements, but low correlation with patient-reported outcomes. Most commonly used tools were found to be either insufficient or indeterminate in their measurement properties.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Tara Behroozian, Lauren Milton, Liying Zhang, Julia Lou, Irene Karam, Emily Lam, Gina Wong, Ewa Szumacher, Edward Chow
Summary: This study revealed significant discrepancies between patient-reported outcomes (PROs) and clinician-reported outcomes (CROs) when assessing breast radiation dermatitis (RD). Clinicians significantly underreported all skin symptom assessment items compared to patients. The majority of patients used moisturizing creams as a prophylactic measure. The findings highlight the need for improved RD symptom assessment and support the development of a new tool with components from both patients and clinicians.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Lauren Milton, Tara Behroozian, Nim Li, Liying Zhang, Julia Lou, Irene Karam, Matt Wronski, Erin McKenzie, Gord Mawdsley, Yasmeen Razvi, Edward Chow, Mark Ruschin
Summary: The Edmonton Symptom Assessment System (ESAS) is an effective tool for assessing fatigue, anxiety, and wellbeing in breast cancer patients undergoing radiotherapy (RT). However, it does not accurately reflect the severity of radiation dermatitis (RD) symptoms. Further research is needed to develop a new tool specifically designed to assess the burden of RD in RT for breast cancer.
CLINICAL BREAST CANCER
(2022)
Review
Oncology
Samuel Finkelstein, Lauren Kanee, Tara Behroozian, Julie Ryan Wolf, Corina van den Hurk, Edward Chow, Pierluigi Bonomo
Summary: Comparison of RD clinical practice guidelines published between 2010 and 2021 by different organizations revealed some agreement on treatment recommendations for acute RD and chronic RT-induced skin toxicities, such as the use of topical corticosteroids, silver sulfadiazine, washing, and deodorant. However, there is still minimal consensus on optimal dressing or barrier film for RD prophylaxis or management, indicating the need for further research to establish optimal treatments.
SUPPORTIVE CARE IN CANCER
(2022)
Editorial Material
Oncology
Tara Behroozian, Inmaculada Navarro, Peter Hoskin, Candice Johnstone, Abram Recht, Johan Menten, Eva Oldenburger, Yvette van der Linden, Joanne M. van der Velden, Quynh-Nhu Nguyen, Charles B. Simone, Peter Johnstone, Stephen Lutz, Lauren Milton, Nicolaus Andratschke, Jonas Willmann, Joanna Kazmierska, Mateusz Spalek, Edward Chow, Srinivas Raman
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Oncology
Tara Behroozian, Lauren Milton, Irene Karam, Liying Zhang, Keyue Ding, Julia Lou, Francois Gallant, Eileen Rakovitch, William Tran, Hany Soliman, Eric Leung, Danny Vesprini, Ewa Szumacher, Hanbo Chen, Elysia Donovan, Jacqueline Lam, Silvana Spadafora, Matt Wronski, Chris Lavoie, Natalie Walde, Emily Lam, Gina Wong, Erin McKenzie, Krista Ariello, Samantha Kennedy, Saba Shariati, Katherine Carothers, Glen Gonzales, Yulya Kagan, Edward Chow
Summary: A confirmatory randomized controlled trial was conducted to evaluate the effectiveness of Mepitel film (MF) in reducing radiation dermatitis (RD) in patients undergoing breast radiotherapy. The results showed that MF significantly reduced the incidence of grade 2 or 3 RD and had positive effects on patient-reported outcomes and clinician-reported outcomes.
JOURNAL OF CLINICAL ONCOLOGY
(2023)